Malignant Digestive System Neoplasm
Back to Diseases List
Associated Genetic Biomarkers
Malignant digestive system neoplasms most frequently harbor alterations in TP53, KRAS, APC, SMAD4, and PIK3CA .
TP53 Mutation, KRAS Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, and KRAS Exon 2 Mutation are the most common alterations in malignant digestive system neoplasm .
There is 1 clinical trial for malignant digestive system neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains malignant digestive system neoplasm as an inclusion criterion, 1 is phase 1 (1 open).
ERBB2 and HER2 are the most frequent gene inclusion criteria for malignant digestive system neoplasm clinical trials .
Zanidatamab is the most common intervention in malignant digestive system neoplasm clinical trials.
Significant Genes in Malignant Digestive System Neoplasm
ERBB2 is altered in 5.64% of malignant digestive system neoplasm patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant digestive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant digestive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) .
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.